reports
- GlobalData Healthcare Department
ESSA Pharma Inc (EPI) - Financial Analysis Review
ESSA Pharma Inc (EPI) - Financial Analysis Review Summary Essa Pharma Inc (Essa Pharma) is a clinical-stage pharmaceutical company that carries out the development of small molecule drugs for the treatment castration-resistant prostate cancer (CRPC). The company’s lead product candidate, EPI-506, disrupts androgen receptor (AR) transcriptional activity through selectively blocking the N-terminal domain of the AR. It also conducts research on prostate cancer and the androgen receptor, metasta...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.